/

Sociétés

Gu

Non vérifié

Guardant Health, Inc.

Ce que nous écrivons

BiotechnologieIndustrieOncologieSantéSanté Publique

111 communiqués de presse

Voir tous les communiqués de presse

18/03/2026

Événements

Industrie

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

Source

Guardant Health, Inc.

Émetteur

1.00

0

16/03/2026

Technique

Hygiène alimentaire

Associations/Professionnels

Santé

Oncologie

Logiciels

Assurances

Finance

Marché du travail

Industrie

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

Source

Guardant Health, Inc.

Émetteur

1.00

0

13/03/2026

Analyse de marché

Industrie

Oncologie

Santé

Biotechnologie

Santé Publique

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

Source

Guardant Health, Inc.

Émetteur

1.00

0

10/03/2026

Marché du travail

Industrie

Oncologie

Santé

Santé Publique

Management

Biotechnologie

Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

Source

Guardant Health, Inc.

Émetteur

1.00

0

04/03/2026

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

Source

Guardant Health, Inc.

Émetteur

1.00

0

03/03/2026

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

Source

Guardant Health, Inc.

Émetteur

1.00

0

27/02/2026

Marché financier

Finance

Santé Publique

Santé

Oncologie

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source

Guardant Health, Inc.

Émetteur

1.00

0

19/02/2026

Biotechnologie

Équipement médical et sanitaire

Santé

Oncologie

Web et Réseaux Sociaux

Téléphonie et Divers

Marché financier

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Source

Guardant Health, Inc.

Émetteur

1.00

0

03/02/2026

Technique

Associations/Professionnels

Logiciels

Santé

Industrie pharmaceutique

Oncologie

Événements

Guardant Health to Participate in Upcoming Investor Conferences

Source

Guardant Health, Inc.

Émetteur

1.00

0

02/02/2026

Industrie

Oncologie

Santé

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

Source

Guardant Health, Inc.

Émetteur

1.00

0

Followers

0

Compatibilité

0